Search results for "030211 gastroenterology & hepatology"

showing 10 items of 1275 documents

Canine pancytopoenia and hemophagocytic lymphohistiocytosis

2018

0403 veterinary science03 medical and health sciencesHemophagocytic lymphohistiocytosis0302 clinical medicine040301 veterinary sciencesbusiness.industryImmunologyMedicine030211 gastroenterology & hepatology04 agricultural and veterinary sciencesSmall Animalsbusinessmedicine.diseaseJournal of Small Animal Practice
researchProduct

Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?

2018

Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common cause of chronic liver disease in Western countries, accounting for 20–30% of general population and reaching a prevalence of 55% in patients with type 2 diabetes mellitus (T2DM). Insulin resistance plays a key role in pathogenic mechanisms of NAFLD. Many drugs have been tested but no medications have yet been approved. Antidiabetic drugs could have a role in the progression reduction of the disease. The aim of this review is to summarize evidence on efficacy and safety of antidiabetic drugs in patients with NAFLD. Metformin, a biguanide, is the most frequently used drug in the treatment of T2DM. To date 15 randomized controlled t…

3003medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentlcsh:Medicinelcsh:RS1-441Pharmaceutical Sciencehepatic cirrhosis030209 endocrinology & metabolismReviewChronic liver diseaseGastroenterologylcsh:Pharmacy and materia medica03 medical and health sciences0302 clinical medicineInsulin resistanceInternal medicineDiabetes mellitusDrug DiscoverymedicineBiguanidebusiness.industryLiraglutideInsulinlcsh:RFatty liverThiazolidinedionenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseLiraglutidemedicine.diseaseMetforminMetforminHepatic cirrhosiMolecular Medicine030211 gastroenterology & hepatologyThiazolidinedionesnon-alcoholic steatohepatitisbusinessNon-alcoholic steatohepatitimedicine.drugPharmaceuticals (Basel, Switzerland)
researchProduct

The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four European countries

2021

Eliminació del VHC; Punt d'equilibri; Infecció d'hepatitis C Eliminación del VHC; Punto de equilibrio; Infección de hepatitis C HCV elimination; Break-even; Hepatitis C infection Background and Aims We assessed the clinical and economic impact of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) in England, Italy, Romania and Spain. Methods An HCV progression Markov model was developed considering DAA eligibility and population data during the years 2015-2019. The period of time to recover the investment in DAAs was calculated as the cost saved by avoiding estimated clinical events for 1000 standardized treated patients. A delayed treatment scenario because of coronavirus di…

:Health Care Economics and Organizations::Economics::Costs and Cost Analysis::Cost Control::Cost Savings [HEALTH CARE]DiseaseHepacivirusmedicine.disease_cause:Digestive System Diseases::Liver Diseases::Hepatitis::Hepatitis Viral Human::Hepatitis C [DISEASES]0302 clinical medicineCost of IllnessMedicine:Other subheadings::/therapeutic use [Other subheadings]Economic impact analysisChronicExit strategyevenLiver NeoplasmsHealth services researchhealthInvestment (macroeconomics)Hepatitis C:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Anti-Infective Agents::Antiviral Agents [CHEMICALS AND DRUGS]break‐EnglandItalyHCV elimination030220 oncology & carcinogenesisOriginal Article030211 gastroenterology & hepatologyLiver Disease and Public HealthHumanHepatitis C virusSettore SECS-P/03hepatitis C infectionMedicaments antivírics- Ús terapèuticAntiviral AgentsTime-to-Treatment03 medical and health sciencesbreak-evenHumansbusinessDisease burdenDAAAntiviral Agent:economía y organizaciones para la atención de la salud::economía::costes y análisis de costes::control de costes::ahorro de costes [ATENCIÓN DE SALUD]HepaciviruHepatology:Otros calificadores::/uso terapéutico [Otros calificadores]business.industryRomania:enfermedades del sistema digestivo::enfermedades hepáticas::hepatitis::hepatitis viral humana::hepatitis C [ENFERMEDADES]COVID-19break‐evenDAAsHepatitis C ChronicEstalvi i inversióHcv eliminationCost of IllneSpain:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antiinfecciosos::antivíricos [COMPUESTOS QUÍMICOS Y DROGAS]Communicable Disease ControlVirus de l'hepatitis CbusinessDemography
researchProduct

Small bowel obstruction after laparoscopic gastrectomy: An atypical clinical presentation. Report of a case

2020

Abstract Introduction Postoperative adhesions represent the most common cause of acute small bowel obstruction (80%) and are usually a consequence of abdomino-pelvic surgery performed with open technique. Presentation of case A 45-year-old black man arrived at the emergency room with abdominal pain and distension three months after laparoscopic distal gastrectomy with Roux-en-Y anastomosis performed for benign pyloric stenosis. CT abdominal scan revealed some air-fluid levels in the center of the abdomen with distension of proximal jejunal loops caused by intestinal adhesions. Laparoscopic adhesiolysis was performed to restore the intestinal transit. Discussion The formation of adhesions is…

Abdominal painmedicine.medical_specialtyAdhesiolysismedicine.medical_treatmentCase ReportAnastomosisDistensionPyloric stenosis03 medical and health sciences0302 clinical medicineLaparotomymedicineLaparoscopyPostoperative adhesionsmedicine.diagnostic_testbusiness.industrySmall bowel obstructionmedicine.diseaseSurgeryBowel obstructionmedicine.anatomical_structure030220 oncology & carcinogenesisLaparoscopic gastrectomyAbdomenLaparoscopy030211 gastroenterology & hepatologySurgerymedicine.symptombusinessInternational Journal of Surgery Case Reports
researchProduct

Clinical response to linaclotide at week 4 predicts sustained response in irritable bowel syndrome with constipation and improvements in digestive an…

2019

Background:Linaclotide is approved for the treatment of moderate-to-severe irritable bowel syndrome (IBS) with constipation (IBS-C) in adults. This study aimed to assess factors predictive of a clinical response and improvements in non-IBS symptoms with linaclotide treatment in a Spanish patient population.Methods:In this open-label phase IIIb study, patients with moderate-to-severe IBS-C received linaclotide 290 μg once daily for 12 weeks. The primary endpoint was clinical response at week 12, defined as >30% reduction in IBS symptom severity score (IBS-SSS) or IBS-SSS <75 plus self-reported response of feeling ‘better’ or ‘much better’ versus the baseline. Digestive nonintestinal an…

Abdominal painmedicine.medical_specialtyConstipation03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinefunctional gastrointestinal diseasesmedicinelcsh:RC799-869LinaclotideIrritable bowel syndromeOriginal Researchirritable bowel syndromebusiness.industryGastroenterologyabdominal painconstipationmedicine.diseasechemistry030220 oncology & carcinogenesisSustained response030211 gastroenterology & hepatologylcsh:Diseases of the digestive system. Gastroenterologymedicine.symptombusinessTherapeutic Advances in Gastroenterology
researchProduct

Case Report: Primary Peritonitis as the Onset of Pediatric Ménétriers Disease

2021

Introduction: Primary peritonitis (PP) and Ménétrier's Disease (MD) are both rare conditions among pediatric population. Although about 150 MD cases have been described in the scientific literature to date, its onset with a PP is an unusual condition.Case Presentation: We present a case of an 11-year-old boy who was admitted to our unit because of abdominal pain and distension. Complementary tests showed ascites, bilateral pleural effusion, leukocytosis, increased acute phase reactants and hypoproteinemia with hypoalbuminemia. Laparoscopy ruled out appendicitis or visceral perforations and exposed purulent peritoneal fluid, compatible with PP. Biochemical stool analysis showed increased cle…

Abdominal painmedicine.medical_specialtyPediatricsGastroenterology03 medical and health sciencesHypoproteinemia0302 clinical medicine030225 pediatricsInternal medicineMénétrier's diseaseAscitesmedicinecase reportEnteropathyHypoalbuminemiaprotein-losing enteropathybusiness.industryProtein losing enteropathylcsh:RJ1-570lcsh:Pediatricsmedicine.diseaseAppendicitisMénétrier's diseasehypertrophic gastropathyPediatrics Perinatology and Child Health030211 gastroenterology & hepatologymedicine.symptombusinessprimary peritonitisFrontiers in Pediatrics
researchProduct

Staged acute mesenteric and peripheral ischemia treatment in COVID-19 patient: Case report

2021

Introduction COVID-19 is an infectious disease that has been associated not only with respiratory complications. The COVID-19 disease includes, also damage to other organ systems as well as coagulopathy. The present report describes a case of COVID-19 presenting with acute mesenteric ischemia (AMI) and subsequent acute limb ischemia (ALI). Presentation of case An 84-years old hospitalized female patient presenting diabetes and recent COVID-19 reported acute onset of abdominal pain and typical findings of AMI. The CT-angiography confirmed the AMI secondary to a superior mesenteric artery (SMA) occlusion. The patient was managed through an endovascular approach using a SMA mechanical thrombec…

Abdominal painmedicine.medical_specialtyResuscitationmedicine.medical_treatmentRevascularizationSettore MED/22 - Chirurgia VascolareAcute mesenteric ischemia03 medical and health sciences0302 clinical medicinemedicine.arteryCase reportCoagulopathyMedicineEmbolizationSuperior mesenteric arterycardiovascular diseasesAcute limb ischemiabusiness.industryThrombolysisExplorative laparotomymedicine.diseaseSurgery030220 oncology & carcinogenesis030211 gastroenterology & hepatologySurgerymedicine.symptombusinessMechanical thrombectomyCOVID 19International Journal of Surgery Case Reports
researchProduct

NEW THERAPEUTIC PERSPECTIVES IN IRRITABLE BOWEL SYNDROME: TARGETING LOW-GRADE INFLAMMATION, IMMUNO-NEUROENDOCRINE AXIS, MOTILITY, SDECRETION AND BEYO…

2017

Irritable bowel syndrome (IBS) is a chronic, recurring, and remitting functional disorder of the gastrointestinal tract characterized by abdominal pain, distention, and changes in bowel habits. Although there are several drugs for IBS, effective and approved treatments for one or more of the symptoms for various IBS subtypes are needed. Improved understanding of pathophysiological mechanisms such as the role of impaired bile acid metabolism, neurohormonal regulation, immune, dysfunction, the epithelial barrier and the secretory properties of the gut has led to advancements in the treatment of IBS. With regards to therapies for restoring intestinal permeability, multiple studies with prebiot…

Abdominal painmedicine.medical_specialtyReviewFunctional disorderGastroenterologyPermeabilityBile Acids and Salts03 medical and health scienceschemistry.chemical_compound0302 clinical medicineGastrointestinal AgentsMesalazineInternal medicineImmunoendocrine axisTherapy; Low grade inflammation; Motility; Secretion; Irritable bowel syndrome; Immunoendocrine axismedicineHumansSecretionIrritable bowel syndromeInflammationClinical Trials as TopicGastrointestinal agentSettore MED/12 - GastroenterologiaLow grade inflammationIntestinal permeabilitybusiness.industryGastroenterologyMotilityDrugs InvestigationalGeneral Medicinemedicine.diseaseAbdominal PainRifaximinIntestinesClinical trialIrritable bowel syndromeSettore MED/18 - Chirurgia GeneraleTreatment Outcomechemistry030220 oncology & carcinogenesis030211 gastroenterology & hepatologyTherapymedicine.symptomGastrointestinal Motilitybusiness
researchProduct

Laparoscopic management of cholecystocolonic fistula: A case report and a brief literature review

2020

Highlights • Cholecystoenteric fistula is a rare and late complication of cholelithiasis. • We report a case of cholecysto-colonic fistula with hepatic flexure management by laparoscopic approach, a 64 years old male patients with fever of an unknown origins for two months and abdominal pain. • We performed laparoscopic cholecystectomy and repaired colonic wall with intra-corporeal sutures. • The laparoscopic management of cholecystoeneteric fistula is a feasible and safe procedure but the operative strategy should be individualized.

Abdominal painmedicine.medical_specialtymedicine.medical_treatmentFistulaColonoscopyComplicated cholelithiasisArticle03 medical and health sciences0302 clinical medicineMedicineLaparoscopySurgical teammedicine.diagnostic_testbusiness.industryGallbladderGeneral surgerymedicine.diseasemedicine.anatomical_structureCholecystocolonic fistula030220 oncology & carcinogenesis030211 gastroenterology & hepatologySurgeryCholecystectomyLaparoscopyPresentation (obstetrics)medicine.symptombusinessComplicated cholelithiasiInternational Journal of Surgery Case Reports
researchProduct

The Intention-to-Treat Effect of Bridging Treatments in the Setting of Milan Criteria–In Patients Waiting for Liver Transplantation

2019

In patients with hepatocellular carcinoma (HCC) meeting the Milan criteria (MC), the benefit of locoregional therapies (LRTs) in the context of liver transplantation (LT) is still debated. Initial biases in the selection between treated and untreated patients have yielded conflicting reported results. The study aimed to identify, using a competing risk analysis, risk factors for HCC-dependent LT failure, defined as pretransplant tumor-related delisting or posttransplant recurrence. The study was registered at www.clinicaltrials.gov (identification number NCT03723304). In order to offset the initial limitations of the investigated population, an inverse probability of treatment weighting (IP…

Ablation TechniquesGraft RejectionMaleTime FactorsHepatocellular carcinomaIMPACTmedicine.medical_treatmentSettore MED/18 - CHIRURGIA GENERALEintent to treatLOCOREGIONAL THERAPYKaplan-Meier Estimate030230 surgeryLiver transplantationLIVER TRANSPLANTATION HEPATOCELLULAR CARCINOMA RISK FACTORS OUTCOME PROGNOSTIC SCOREGastroenterologyLiver disease0302 clinical medicineRisk FactorsHEPATOCELLULAR-CARCINOMAHepatocellular carcinoma liver transplantation risk factors intent to treat prognostic score waiting listeducation.field_of_studyLiver NeoplasmsAge FactorsDEATHwaiting listMiddle AgedCANCERprognostic scoreIntention to Treat AnalysisTIMETreatment OutcomeHepatocellular carcinomaDisease ProgressionSURVIVAL030211 gastroenterology & hepatologyFemalemedicine.symptommedicine.medical_specialtyCarcinoma HepatocellularWaiting ListsALPHA-FETOPROTEINPopulationMilan criteriamRECISTRisk AssessmentLesionalpha-fetoprotein03 medical and health sciencesSex FactorsInternal medicinePreoperative CaremedicineHumansHepatology; gastroenterology; hepatocelluar cancer; locoregional therapieseducationRECURRENCEOUTCOMETransplantationLiver transplantationIntention-to-treat analysisHepatologybusiness.industryHEPATOCELLULAR-CARCINOMA; ALPHA-FETOPROTEIN; LOCOREGIONAL THERAPY; RECURRENCE; CANCER; MODEL; TIME; SURVIVAL; IMPACT; DEATHlocoregional therapymedicine.diseaseSettore MED/18Liver TransplantationMODELhepatocellular cancerTumor progressionSurgerybusinessFollow-Up Studies
researchProduct